ERBB2 and lymphangioma: We have described in this clinical case, a patient with a long-term survival after the diagnosis of CNS metastases and suspicion of LM, with the use of HER2-targeted treatment, including the novel antibody drug conjugate T-DXd, with a consistent and maintained response to this treatment, with tolerable toxicity and thus preserved quality of life.